Decreased device related thrombus and enhanced neo-endocardial tissue maturation with a new generation left atrial appendage closure (LAAC) device. An anticoagulation and antiplatelet free canin study

27 August 2022 (15:15 - 15:45)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Walid Saliba

Cleveland Clinic, Cleveland (United States of America)

4 More presentations in this session

Presentation thumbnail

Risk of stroke and transient ischemic attack after elective cardioversion of atrial fibrillation: A nationwide study in Finland

Mrs S. Itainen-Stromberg (Helsinki, FI)

Abstract Slides

Presentation thumbnail

Clinical risk prediction for left atrial appendage thrombus among patients with atrial fibrillation

Professor P. Kistler (Melbourne, AU)

Abstract Slides

Presentation thumbnail

Left atrial appendage occlusion versus standard of care in patients with atrial fibrillation and a prior thrombo-embolic event despite oral anticoagulant therapy: a propensity score matched comparison

Professor L. Boersma (Nieuwegein, NL)

Abstract Slides

Presentation thumbnail

Impact of ABC pathway adherence in high-risk patients with atrial fibrillation: an analysis from the ESC-EHRA EORP-AF long-term general registry

Doctor W. Ding (Liverpool, GB)

Abstract Slides

Access the full session

Session thumbnail

Stroke prevention by anticoagulation and appendage occlusion in atrial fibrillation

The Event

Event poster

ESC Congress 2022

27 August 2022 15:15 CET

You may be interested in

Congress Presentation

Left atrial appendage closure in atrial fibrillation: gaps in knowledge

Congress Session

Stroke prevention in atrial fibrillation: do not forget the left atrial appendage!

Congress Session

LAAC and AF ablation are evolving, are you?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources